
Adding Sunharbo (asundexian), a first-in-class Factor XI inhibitor, to single or dual antiplatelet therapy reduces ischemic stroke risk without increasing the risk of major bleeding.
Prompted by the proliferation of new therapies in the field, the American College of Rheumatology has updated its guidelines for the management of rheumatoid arthritis.






